Fenoldopam_mesylate_DataSheet_MedChemExpress
盐酸多巴酚丁胺-安全技术说明书MSDS
第一部分化学品及企业标识化学品中文名：盐酸多巴酚丁胺化学品英文名：4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]pyrocatechol hydrochloride CAS No.：49745-95-1分子式：C18H24ClNO3产品推荐及限制用途：工业及科研用途。
第二部分危险性概述紧急情况概述吞咽有害。
皮肤接触有害。
吸入有害。
怀疑对生育能力或胎儿造成伤害。
GHS危险性类别急性经口毒性类别 4急性经皮肤毒性类别 4急性吸入毒性类别 4生殖毒性类别 2标签要素：象形图：警示词：警告危险性说明：H302 吞咽有害H312 皮肤接触有害H332 吸入有害H361 怀疑对生育能力或胎儿造成伤害●预防措施：—— P264 作业后彻底清洗。
—— P270 使用本产品时不要进食、饮水或吸烟。
—— P280 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
—— P261 避免吸入粉尘/烟/气体/烟雾/蒸气/喷雾。
—— P271 只能在室外或通风良好处使用。
—— P201 使用前取得专用说明。
—— P202 在阅读并明了所有安全措施前切勿搬动。
●事故响应：—— P301+P312 如误吞咽：如感觉不适，呼叫解毒中心/ 医生—— P330 漱口。
—— P302+P352 如皮肤沾染：用水充分清洗。
—— P312 如感觉不适，呼叫解毒中心/医生—— P362+P364 脱掉沾染的衣服，清洗后方可重新使用—— P304+P340 如误吸入：将人转移到空气新鲜处，保持呼吸舒适体位。
—— P308+P313 如接触到或有疑虑：求医/就诊。
●安全储存：—— P403+P233 存放在通风良好的地方。
保持容器密闭。
—— P405 存放处须加锁。
●废弃处置：—— P501 按当地法规处置内装物/容器。
物理和化学危险：无资料。
健康危害：吞咽有害。
皮肤接触有害。
吸入有害。
凯纷说明书
请仔细阅读说明书并在医师指导下使用以下患者禁用：1.已知对本品过敏的患者。
2.服用阿司匹林或其他非甾体类抗炎药后诱发哮喘、荨麻疹或过敏反应的患者。
3.禁用于冠状动脉搭桥手术（CABG）围手术期疼痛的治疗。
4.有应用非甾体抗炎药后发生胃肠道出血或穿孔病史的患者。
5.有活动性消化道溃疡/出血，或者既往曾复发溃疡/出血的患者。
6.重度心力衰竭患者、高血压患者。
7.严重的肝、肾及血液系统功能障碍患者。
8.正在使用依诺沙星、洛美沙星、诺氟沙星的患者。
【药品名称】通用名称：氟比洛芬酯注射液商品名称：凯纷®英文名称：Flurbiprofen Axetil Injection汉语拼音：Fubiluofenzhi Zhusheye【成份】本品主要成分为氟比洛芬酯，其化学名称为：（±）2-（2-氟-4-联苯基）丙酸-1-乙酰氧基乙酯其结构式为：分子式：C19H19FO4分子量：330.36辅料：精制大豆油、精制卵磷脂、浓甘油、磷酸氢二钠、枸橼酸、注射用水【性状】本品为白色乳液，略带粘性，有特异性气味。
【适应症】术后及癌症的镇痛。
【规格】5ml:50mg【用法用量】通常成人每次静脉给予氟比洛芬酯50mg，尽可能缓慢给药（1分钟以上），根据需要使用镇痛泵，必要时可重复应用。
并根据年龄、症状适当增减用量。
一般情况下，本品应在不能口服药物或口服药物效果不理想时应用。
【不良反应】1．严重不良反应：罕见休克、急性肾衰、肾病综合征、胃肠道出血、伴意识障碍的抽搐。
2．在氟比洛芬的其他制剂的研究中还观察到以下严重不良反应：罕见再生障碍性贫血、中毒性表皮坏死症（Lyell综合症）、剥脱性皮炎。
3．一般的不良反应：（1）注射部位：偶见注射部位疼痛及皮下出血；（2）消化系统：有时出现恶心、呕吐，转氨酶升高，偶见腹泻，罕见胃肠出血；（3）精神和神经系统：有时出现发热，偶见头痛、倦怠、嗜睡、畏寒；（4）循环系统：偶见血压上升、心悸；（5）皮肤：偶见瘙痒、皮疹等过敏反应；（6）血液系统：罕见血小板减少，血小板功能低下。
Cisplatin_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jul.-12-2017Print Date:Jul.-12-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :CisplatinCatalog No. :HY-17394CAS No. :15663-27-11.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 2), H300Serious eye damage (Category 1), H318Carcinogenicity (Category 1B), H3502.2 GHS Label elements, including precautionary statementsPictogramSignal word DangerHazard statement(s)H300 Fatal if swallowed.H318 Causes serious eye damage.H350 May cause cancer.Precautionary statement(s)P201 Obtain special instructions before use.P202 Do not handle until all safety precautions have been read and understood.P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P280 Wear protective gloves/ eye protection/ face protection.P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contactlenses, if present and easy to do. Continue rinsing.P310 Immediately call a POISON CENTER or doctor/ physician.H300 Fatal if swallowed.H318 Causes serious eye damage.H350 May cause cancer. P321 Specific treatment (see supplemental first aid instructions on this label).P330 Rinse mouth.P405 Store locked up.P501 Dispose of contents/ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:CDDP; cis–DiaminodichloroplatinumFormula:Cl2H6N2PtMolecular Weight:300.05CAS No. :15663-27-14. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data available Flash point No data available Evaporation rate No data available Flammability (solid, gas)No data available Upper/lower flammability or explosive limits No data available Vapor pressure No data available Vapor density No data available Relative density No data available Water Solubility No data available Partition coefficient No data available Auto-ignition temperature No data available Decomposition temperature No data available Viscosity No data available Explosive properties No data available Oxidizing properties No data available 9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 2Additional informationRTECS No.: TP2450000May cause liver irregularities.This information is based on our current knowledge. However the chemical, physical, and toxicological properties have not been completely investigated.12. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONAcute Health Hazard, Chronic Health Hazard.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
阿司咪唑
合成方法
合成方法
化合物(I)和碘甲烷在乙醇中回流8h，环合得到化合物(Ⅱ)。再水解脱去酯基，得到化合物(Ⅲ)。用对甲氧 基苯乙基溴进行N-烷基化，得化合物(Ⅳ)。再用对氟苄基溴烷基化，得阿司咪唑。
1. 1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮的制备
在反应瓶中加入2-羟基苯并咪唑5.0g(37.3mmol)和NaH 1.6g(53mmol)(NaH含量大约为80%,浸入矿物油中) 的DMF 100ml的悬浮液.加毕.在60ºC.(最好有N2保护)搅拌反应1h.再加入4-氟苄基氯(FBC)5.4g(37mmol),加热 ( 6 0 ºC ) 搅 拌 反 应 5 . 5 h . 冷 却 至 室 温 后 加 入 冰 水 7 0 0 m l , 用 二 氯 甲 烷 ( 5 0 0 m l × 2 ) 提 取 . 有 机 层 用 食 盐 水 洗 . 无 水 N a 2 S O 4 干燥.过滤.滤液减压浓缩.剩余物用石油醚析晶.得1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮固体8.0g,为无色 结 晶 m p 1 7 8 ~ 1 7 9 ºC , 收 率 8 8 % .
治疗措施
阿司咪唑中毒的治疗要点为： 1.大量摄入者予洗胃，后灌服活性炭和导泻。 2.对心肌抑制和Q-T间期延长者予5%碳酸氢钠250ml静注可能有效。 3.对症、支持治疗。
专家点评
专家点评
阿司咪阿司咪唑自1983年上市以来，在许多国家得到了广泛应用。国外研究显示阿司咪唑治疗荨麻疹的总有 效率为74%。国内的一项多中心双盲安慰剂对照试验表明阿司咪唑对急性荨麻疹的总有效率为82.9%，对慢性荨麻 疹的总有效率为86.0%，均显著高于安慰剂，主要不良反应为嗜睡、倦怠、口干等，连续用药3个月的患者中，半 数有食欲及体重增加。阿司咪唑的心脏毒性虽然发生率较低，但由于后果严重，已限制了它的应用。阿司咪唑为 强效和长效的H1受体拮抗剂，无中枢镇静和抗毒蕈碱样作用。代谢产物去甲阿司咪唑仍有抗胆胺作用。长期服用 可增进食欲和增加体重，服用过量可引起心脏Q-T间期延长和室性心律失常。适用于各种原因引起过敏性疾病。
288-32-4,咪唑,技术规格说明书(SDS)
产品技术规格说明书由上海创赛科技有限公司收集整理，仅作参考使用。
英文名称：
Glyoxaline
英文别名：
1H-Imidazole;IMZ;Glyoxaline;Imidazole Glyoxaline;Imidazole, ULTROL Grade;1,3-diazole;Imidazole [for Buffer];Imidazole Zone Refined (number of passes:30);Imidazole [for Fluorimetric Analysis];Imidazole;1,3-diaza-2,4-cyclopentadiene;1,3-Diaza-2,4-cyclopentadiene,Glyoxaline;1,3-imidazole;1-imidazole;glioksal;GLYOXALIN;IMD;Imidazoie;Imidazol;Imidazole buffer;IMINAZOLE;Imutex;LMIDAZOLE;Miazole;Miazole ;Pyrro[b]Monazole;1,3-Diazole
288-32-4|咪唑,技术规格说明书(SDS)
简介：
咪唑，Imidazole是一种平面五元环, 是一种高极性化合物, 已被广泛用作腐蚀抑制剂。
咪唑物理化学性质：
密度
1.1±0.1 g/cm3
沸点
257.0±9.0 °C at 760 mmHg
熔点
88-91 °C(lit.)
分子式
C3H4N2
分子量
测定：≥99% 生物技术级
Fenoldopam_67227-56-9_DataSheet_MedChemExpress
Product Name:Fenoldopam CAS No.:67227-56-9Cat. No.:HY-B0735Product Data SheetMWt:305.76Formula:C16H16ClNO3Purity :>98%Solubility:DMSOy Mechanisms:Biological Activity:Fenoldopam(SKF 82526)is a drug and synthetic benzazepine derivative which acts as a selectivePathways:GPCR/G protein; Target:Dopamine Receptor Pathways:Neuronal Signaling; Target:Dopamine Receptor Fenoldopam(SKF 82526) is a drug and synthetic benzazepine derivative which acts as a selectiveD1 receptor partial agonist.Target: D1 Receptor Fenoldopam is a selective dopamine-1 (DA1) agonist with natriuretic/diuretic properties.Fenoldopam stimulated cAMP accumulation in LLC-PK1 cells in a dose-dependent manner, an effect which could be blocked by the DA1-selective antagonist Sch 23390. Although fenoldopam was more potent than DA (EC50 55.5 +/- 7.75 nM vs. 1.65 +/- 0.64 microM) in stimulating cAMP accumulation in LLC-PK1 cells, the maximum stimulation obtained by fenoldopam was only 37% of the maximum stimulation obtained by DA(Emax 13.0 +/- 2.95 pmol/mg of protein vs. 35.6 +/- 10.19References:[1]. Grenader, A. and D.P. Healy, Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors inLLC-PK1 cells. J Pharmacol Exp Ther, 1991. 258(1): p. 193-8.[2]. Nichols, A.J., R.R. Ruffolo, Jr., and D.P. Brooks, The pharmacology of fenoldopam. Am J y (p g ppmol/mg of protein) [1]. Fenoldopam is a selective dopamine1 (DA1) receptor agonist. Most of the DA1 receptor agonist activity of fenoldopam resides in the R-enantiomer, which also sho...[]p gy pHypertens, 1990. 3(6 Pt 2): p. 116S-119S.Caution: Not fully tested. For research purposes onlyMedchemexpress LLC18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
甲磺酸沙芬酰胺质量标准
甲磺酸沙芬酰胺质量标准
甲磺酸沙芬酰胺（Safinamide Mesylate）是一种新型单胺氧化酶B（MAO-B）选择性抑制剂，用于治疗帕金森病。
关于甲磺酸沙芬酰胺的质量标准，以下是一些参考信息：
1. 化学名称：N-[(2S)-2-氨基-3-[[(1R)-1-氟-2-羟基-乙基]氨基]-2-氧代-丙基]-苯甲酰胺甲磺酸盐。
2. 分子式：C18H23FN2O5S。
3. 分子量：385.42。
4. 结构式：
HCN | N = C = O | C - N - C - O - CH3 | C - F | C - OH
5. 甲磺酸沙芬酰胺的质量标准主要包括以下几个方面：
- 外观：通常为白色或类白色结晶性粉末。
- 溶解性：甲磺酸沙芬酰胺在水或甲醇中溶解性良好。
- 纯度：通过高效液相色谱（HPLC）等方法测定甲磺酸沙芬酰胺的纯度，要求不低于98%。
- 有关物质：甲磺酸沙芬酰胺原料药中有关物质（如杂质）的含量要求较低，通常要求不超过0.5%。
- 水分：甲磺酸沙芬酰胺的水分含量要求控制在一定范围内，通常不超过1.0%。
- 炽灼残渣：通过炽灼法测定甲磺酸沙芬酰胺的炽灼残渣含量，要求不超过0.1%。
- 酸碱度：甲磺酸沙芬酰胺溶液的酸碱度要求在一定范围内，通
常控制在4.5-7.5。
6. 包装：甲磺酸沙芬酰胺通常采用密封包装，以防止受潮和污染。
以上仅为甲磺酸沙芬酰胺质量标准的参考信息，实际生产、研究和应用中，还需根据相关法规、标准和实际需求进行详细规定。
迷迭香酸对过氧化氢处理下的皮肤黑色素瘤的抗氧化作用(原文翻译)
迷迭香酸（罗丹酚酸）对H2O2处理过的皮肤黑色素瘤细胞的抗氧化作用Sun Mi Yoo1 and Jeong Ran Kang2*1.韩国光州500-741号东冈大学美容系2.韩国首尔143-701号建国大学生物工程系2009.2.6收到 2009.4.17接收本学科旨在检测迷迭香酸对人工孵育的皮肤黑色素瘤细胞在ROS下的抗氧化作用。
通过XTT比色法，以细胞毒性和抗氧化作用来分析细胞粘附活性，DPPH自由基清除活性以及H2O2处理1-10h和未经处理的两种情况下乳酸脱氢酶的活性。
用20-110 μM 的H2O2处理皮肤黑色素瘤细胞5-7h后，细胞活性的降低呈剂量和时间依赖性。
通过XTT比色法测得H2O2的半抑制浓度（IC50 ）为90μM。
同时H2O2增强了LDH细胞的剂量依赖性。
用50-90μM的H2O2处理8h后测得LDH50为60 μM H2O2。
迷迭香酸能增强细胞活性和DPPH自由基清除活性，降低乳酸盐脱氢酶的活性。
细胞的H2O2处理证实了对人工孵育的皮肤黑色素瘤细胞的强抗氧化作用。
通过H2O2的处理，迷迭香酸能在细胞内能增强细胞活性和DPPH 自由基清除活性，降低乳酸盐脱氢酶的活性。
这被认为是迷迭香酸对ROS（ROS）如H2O2的抗氧化作用。
Key words：DPPH-radical scavenging, LDH, rosmarinic acid, XTT assay关键字：DPPH自由基清除活性，乳酸脱氢酶，迷迭香酸，XTT比色法据研究发现，ROS通过氧化应激对细胞的损伤和一些脑部疾病比如帕金森症或心脏疾病例如心肌梗塞之间有很大的关联[Difazio et al., 1992; Delanty and Dichter, 1998].尤其是研究人员认为ROS是皮肤老化的一个主要的因素后，一直试图从ROS方面研究衰老。
[Yokozawa et al., 1998].据研究表明，ROS的氧化应激会通过萎缩细胞引起各种疾病，例如超氧自由基、H2O2（H2O2）或羟基自由基的巯基蛋白反应中断酶的活性，破坏脱氧RMA（DNA）或RMA（RNA），诱导细胞膜脂质过氧化。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Inhibitors, Agonists, Screening Libraries
Data Sheet
BIOLOGICAL ACTIVITY:
Fenoldopam(SKF 82526) mesylate is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.Target: D1 Receptor
Fenoldopam is a selective dopamine–1 (DA1) agonist with natriuretic/diuretic properties. Fenoldopam stimulated cAMP accumulation in LLC–PK1 cells in a dose–dependent manner, an effect which could be blocked by the DA1–selective antagonist Sch 23390. Although fenoldopam was more potent than DA (EC50 55.5 +/– 7.75 nM vs. 1.65 +/– 0.64 microM) in stimulating cAMP accumulation in
LLC–PK1 cells, the maximum stimulation obtained by fenoldopam was only 37% of the maximum stimulation obtained by DA(Emax 13.0 +/– 2.95 pmol/mg of protein vs. 35.6 +/– 10.19 pmol/mg of protein) [1]. Fenoldopam is a selective dopamine1 (DA1) receptor agonist. Most of the DA1 receptor agonist activity of fenoldopam resides in the R–enantiomer, which also shows weaker alpha 2–adrenoceptor antagonist activity Fenoldopam produces vasodilation in vascular beds that are rich in vascular DA1 receptors [2].References:
[1]. Grenader, A. and D.P. Healy, Fenoldopam is a partial agonist at dopamine–1 (DA1) receptors in LLC–PK1 cells. J Pharmacol Exp Ther, 1991. 258(1): p.193–8.
[2]. Nichols, A.J., R.R. Ruffolo, Jr., and D.P. Brooks, The pharmacology of fenoldopam. Am J Hypertens, 1990. 3(6 Pt 2): p. 116S–119S.
Product Name:
Fenoldopam (mesylate)Cat. No.:
HY-B0735A CAS No.:
67227-57-0Molecular Formula:
C 17H 20ClNO 6S Molecular Weight:
401.86Target:
Dopamine Receptor; Dopamine Receptor Pathway:
GPCR/G Protein; Neuronal Signaling Solubility:
DMSO: ≥ 36 mg/mL
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。